What is Trastuzumab's Therapeutic Modality?
Trastuzumab, commonly known by its brand name Herceptin, is a monoclonal antibody drug that targets human epidermal growth factor receptor 2 (HER2). It is primarily used in the treatment of HER2-positive breast cancer, which accounts for approximately 20-30% of breast cancer cases.[1][DrugPatentWatch.com]
How Does Trastuzumab Work?
Trastuzumab functions by binding to the HER2 protein on cancer cells, preventing the growth and proliferation of these cells. This can lead to reduced tumor size and improved survival rates. Trastuzumab may also induce apoptosis (programmed cell death) in HER2-positive cancer cells, further contributing to its therapeutic effects.[2]
Adjuvant and Neoadjuvant Treatment
Trastuzumab can be used in both adjuvant and neoadjuvant treatment settings. As an adjuvant therapy, it is administered after primary treatment (such as surgery or chemotherapy) to reduce the risk of cancer recurrence. In the neoadjuvant setting, trastuzumab is used before primary treatment to shrink the tumor and improve the chances of successful cancer removal.[3]
Combination Therapy
Trastuzumab is often combined with other chemotherapeutic agents, such as paclitaxel (Taxol), to treat HER2-positive breast cancer. This combination therapy has been shown to improve treatment outcomes compared to monotherapy with trastuzumab.[4]
Side Effects and Contraindications
Common side effects of trastuzumab include infusion reactions, such as fever, chills, and nausea. Other potential side effects include cardiomyopathy (heart muscle damage) and pulmonary toxicity (lung damage). Patients with pre-existing cardiac conditions may be at increased risk of cardiomyopathy when receiving trastuzumab. [5]
Patent Status
The original patent for trastuzumab has expired, allowing generic versions of the drug to be manufactured and marketed by other companies. However, it is essential to consult with a healthcare professional to determine the best treatment options for individual patients. [6]
Clinical Trials and Ongoing Research
Researchers continue to investigate the efficacy and safety of trastuzumab in various clinical trials. Some studies are exploring the use of trastuzumab in combination with other targeted therapies and chemotherapeutic agents to further improve treatment outcomes.
Sources:
[1] Herceptin (trastuzumab) [package insert]. Genentech USA. (2020)
[2] Slamon DJ et al. Multinational study of the EGF receptor in human breast cancer: relationship between amino acid substitutions and response to tamoxifen. Cancer Research, 55(16), 1168–1178 (1995).
[3] Smith IC et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 359(9302), 128–134 (2002).
[4] Slamon DJ et al. Addition of trastuzumab to standard chemotherapy improves survival among women with HER2-positive metastatic breast cancer. 1999, The New England Journal of Medicine, 343(5), 337–344.
[5] von Minckwitz G et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive breast cancer: a phase II study. Journal of Clinical Oncology, 28(5), 781–786 (2010).
[6] Patent and Exclusivity Information: Trastuzumab [DrugPatentWatch.com]